These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 26202742)

  • 1. Assessment of the Usefulness of the Quantitative Methods for the Response Evaluation of Solid Tumors: Analysis Using Four Cancer Types.
    Canals-Lambarri M; Canals-Cifuentes A; Barros-Rocco A; Barros-Nelson P; Mahave-Caceres M; Salman-Boghikian P
    Rev Invest Clin; 2015; 67(3):182-90. PubMed ID: 26202742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment.
    Morse B; Jeong D; Ihnat G; Silva AC
    Abdom Radiol (NY); 2019 Feb; 44(2):766-774. PubMed ID: 30196362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiological monitoring of the treatment of solid tumors in practice.
    Ganten MK; Ganten TM; Schlemmer HP
    Rofo; 2014 May; 186(5):466-73. PubMed ID: 24563412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volume-based response evaluation with consensual lesion selection: a pilot study by using cloud solutions and comparison to RECIST 1.1.
    Oubel E; Bonnard E; Sueoka-Aragane N; Kobayashi N; Charbonnier C; Yamamichi J; Mizobe H; Kimura S
    Acad Radiol; 2015 Feb; 22(2):217-25. PubMed ID: 25488429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
    Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
    Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
    Min SJ; Jang HJ; Kim JH
    Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
    AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure.
    Zacharia TT; Saini S; Halpern EF; Sumner JE
    AJR Am J Roentgenol; 2006 Apr; 186(4):1067-70. PubMed ID: 16554580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target lesion selection: an important factor causing variability of response classification in the Response Evaluation Criteria for Solid Tumors 1.1.
    Keil S; Barabasch A; Dirrichs T; Bruners P; Hansen NL; Bieling HB; Brümmendorf TH; Kuhl CK
    Invest Radiol; 2014 Aug; 49(8):509-17. PubMed ID: 24651664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.
    Kim HS; Kim JH; Yang I
    Lung Cancer; 2014 Sep; 85(3):385-9. PubMed ID: 25074845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
    Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
    Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.
    Chalian H; Töre HG; Horowitz JM; Salem R; Miller FH; Yaghmai V
    Radiographics; 2011; 31(7):2093-105. PubMed ID: 22084190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of volumetric measurement processes in oncology imaging trials for screening and evaluation of tumors as per response evaluation criteria in solid tumors.
    Vemuri RC; Jarecha R; Hwi KK; Gundamaraju R; Maruthikanth A; Kulkarni A; Reddy S
    Asian Pac J Cancer Prev; 2014; 15(5):2375-8. PubMed ID: 24716987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of response criteria for clinical trials of sarcoma treatment.
    Schuetze SM; Baker LH; Benjamin RS; Canetta R
    Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A proposal for the use of tridimensional reconstruction in oncology to better assess tumor stage and response to therapy].
    Guelfi MR; Masoni M; Torelli G; Fonda S; Caramella D
    Radiol Med; 1994 May; 87(5):669-76. PubMed ID: 7516562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
    Mazumdar M; Smith A; Schwartz LH
    J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
    J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
    Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
    Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.
    Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P; Buvat I
    J Nucl Med; 2011 Mar; 52(3):354-61. PubMed ID: 21345787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.